Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
Holding PRAX?
Track your performance easily
PRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.01 - $86.93
Previous CloseN/A
Volume51.58K
Average Volume (3M)342.65K
Market Cap
$1.31B
Enterprise Value$731.25M
Total Cash (Recent Filing)$17.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 12, 2025EPS Estimate
-2.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.29
Shares Outstanding18,637,777
10 Day Avg. Volume314,392
30 Day Avg. Volume342,649
Standard Deviation0.33
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)816.78
Price to Cash Flow (P/CF)-11.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue456.17
Enterprise Value/Gross Profit298.83
Enterprise Value/Ebitda-4.85
Forecast
1Y Price Target
$176.25Price Target Upside149.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Praxis Precision Medicines News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentRelutrigine has received multiple Rare Pediatric Disease Designations, indicating strong support for its product profile in seizure control and reflecting positively on its potential success.
Financial StabilityThe company has a strong financial position with approximately $470 million in cash, providing runway into 2028, supporting its research and development activities.
Pipeline ProgressPromising topline phase 2 EMBOLD trial results on persistent sodium channel inhibitor relutrigine provide strong early evidence that relutrigine will likely be a preferred treatment option for a subset of patients with developmental and epileptic encephalopathies.
Bears Say
Clinical TrialsThe stock is anticipated to trend down due to the delay in the timing of the Ulixa interim analysis.
EarningsReported an EPS of -$2.75, which is 38% lower than the consensus EPS of -$1.99 based on high operating expenses.
Financial PerformanceA net loss of $52M was reported, a notable increase from $33M in a previous quarter, largely due to higher operational expenses.
---
Ownership Overview
10.85% Insiders
19.33% Mutual Funds
3.00% Other Institutional Investors
53.17% Public Companies and Individual Investors
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $33.01 and its highest was $86.93 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $1.31B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Mar 12, 2025 which is in 52 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Nov 06, 2024. The company reported -$2.75 earnings per share for the quarter, missing the consensus estimate of -$1.989 by -$0.761.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -2.85.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 18,637,777 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.75 in its last earnings report, missing expectations of -$1.989. Following the earnings report the stock price went down -1.182%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Among the largest hedge funds holding Praxis Precision Medicines’s share is Perceptive Advisors LLC. It holds Praxis Precision Medicines’s shares valued at 67M.
---
Praxis Precision Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$176.25 (149.86% Upside)
$176.25 (149.86% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 33.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.82%
12-Months-Change
Fundamentals
Return on Equity
-64.34%
Trailing 12-Months
Asset Growth
290.03%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Praxis's pipeline, particularly with promising results in their epilepsy programs and a solid financial position. However, there were concerns about delays in clinical trial timelines and challenges in managing placebo effects, which could impact future outcomes.Read More>---
PRAX Stock 12 Month Forecast
Average Price Target
$176.25
▲(149.86% Upside)
Technical Analysis
Adicet Bio
―
SAGE Therapeutics
―
Cytokinetics
―
Axsome Therapeutics
―
Immunovant
―
Ovid Therapeutics
―
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+74.28%
assigned a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +74.28% per trade.
---